Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 2

Phase 2 (99 companies)

Companies with at least one active program at Phase 2.

Ticker Company Therapeutic areas Phase 2 programs Lead stage Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 5
ACIU AC Immune Neurology Rare 4 Phase 3 11
ACRS Aclaris Therapeutics DermatologyRespiratory 3 Phase 2 7
ACRV Acrivon Therapeutics Oncology 2 Phase 2 5
ACTU Actuate Therapeutics Oncology 1 Phase 2 8
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 4
ADAG Adagene Oncology 3 Phase 2 9
ADCT ADC Therapeutics Oncology 3 Approved 5
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 4 Approved 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 Rare 1 NDA Submitted 8
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 12
DRTS Alpha Tau Medical Oncology 4 Phase 2 5
ALT Altimmune GI/HepatologyMetabolic+1 3 Phase 2 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved 6
ANNX Annexon HematologyNeurology+2 Rare 2 NDA Submitted 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 2 Phase 2 9
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare 3 Phase 2 16
ATAI Atai Beckley Neurology 2 Phase 3 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 2 Approved 12
BMEA Biomea Fusion Metabolic 2 Phase 2 5
CCCC C4 Therapeutics Oncology 1 Phase 2 2
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 4
CLDX Celldex Therapeutics DermatologyImmunology+1 2 Phase 3 7
CLRB Cellectar Biosciences Oncology 3 Approved 11
CRVO CervoMed Neurology Rare 2 Phase 3 5
CLNN Clene Neurology Rare 2 NDA Submitted 5
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 7
CGTX Cognition Therapeutics Neurology 2 Phase 2 2
CMPS COMPASS Pathways Neurology 2 NDA Submitted 3
CGEN Compugen Oncology 1 Phase 3 7
CNTB Connect Biopharma Respiratory 2 Phase 2 4
CRVS Corvus Pharmaceuticals DermatologyOncology 2 Phase 3 4
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted 10
HELP Cybin Neurology 2 Phase 3 3
CYDY CytoDyn NeurologyOncology 2 Phase 2 3
DFTX Definium Therapeutics Neurology 1 Phase 3 4
ELTX Elicio Therapeutics Oncology 1 Phase 2 6
ELOX Eloxx Pharmaceuticals Renal Rare 1 Phase 2 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 2 Phase 3 6
EVMN Evommune DermatologyImmunology+1 4 Phase 2 6
EXEL Exelixis CardiovascularOncology 4 Approved 21
FBRX Forte Biosciences DermatologyGI/Hepatology 1 Phase 2 3
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 2 5
GERN Geron Oncology 1 Approved 3
GHRS GH Research NeurologyWomen's Health 3 Phase 2 4
GOSS Gossamer Bio Cardiovascular Rare 2 Phase 3 4
IMTX Immatics Oncology 1 Phase 2 8
IMMX Immix Biopharma Hematology Rare 1 Phase 2 1
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 4
IBRX ImmunityBio Infectious DiseaseOncology 6 NDA Submitted 16
IMVT Immunovant ImmunologyNeurology Rare 6 Phase 2 6
INAB IN8bio ImmunologyOncology 1 Phase 2 6
IXHL Incannex Healthcare ImmunologyNeurology+1 3 Phase 2 3
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 6
KPRX Kiora Pharmaceuticals Ophthalmology Rare 3 Phase 2 5
KYMR Kymera Therapeutics DermatologyRespiratory Rare 2 Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted 7
LGVN Longeveron CardiovascularMetabolic+1 Rare 2 Phase 2 4
MAIA MAIA Biotechnology Oncology 2 Phase 3 7
MIST Milestone Pharmaceuticals Cardiovascular 1 Phase 3 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 7
NKTR Nektar Therapeutics DermatologyImmunology+2 6 Phase 2 11
NBP NovaBridge Biosciences OncologyOphthalmology 2 Phase 2 6
NRXP NRX Pharmaceuticals Neurology 1 NDA Submitted 5
NRIX Nurix Therapeutics ImmunologyNeurology+1 4 Phase 2 15
OCGN Ocugen Infectious DiseaseOphthalmology Rare 1 Phase 3 13
OCS Oculis Holding NeurologyOphthalmology 1 Phase 3 5
OMER Omeros HematologyNeurology+2 Rare 1 NDA Submitted 7
IRD Opus Genetics Ophthalmology Rare 1 Approved 12
ORKA Oruka Therapeutics DermatologyImmunology Rare 3 Phase 2 6
PEPG PepGen Neurology Rare 1 Phase 2 1
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 7
PCSA Processa Pharmaceuticals GI/HepatologyOncology+1 Rare 2 Phase 2 7
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 2 Phase 3 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 8
RLMD Relmada Therapeutics MetabolicOncology Rare 4 Phase 2 4
REPL Replimune Group Oncology 4 NDA Submitted 5
RYTM Rhythm Pharmaceuticals Metabolic Rare 1 Approved 13
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved 4
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 8
SYRE Spyre Therapeutics Immunology 12 Phase 2 12
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 2 5
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 3
TENX Tenax Therapeutics Cardiovascular Rare 1 Phase 3 2
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved 7
TTRX Turn Therapeutics DermatologyInfectious Disease 2 Phase 3 4
TYRA Tyra Biosciences MetabolicOncology Rare 3 Phase 2 5
VERA Vera Therapeutics Infectious DiseaseRenal Rare 5 Approved 8
VKTX Viking Therapeutics GI/HepatologyMetabolic+1 Rare 6 Phase 3 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare 1 Phase 3 10
VTVT vTv Therapeutics MetabolicRespiratory Rare 3 Phase 3 8
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 5
XNCR Xencor HematologyImmunology+4 Rare 6 Approved 30
ZBIO Zenas BioPharma DermatologyImmunology+1 Rare 2 NDA Submitted 11
ZURA Zura Bio DermatologyImmunology Rare 3 Phase 2 4